Navigation Links
GeoVax Labs, Inc. Announces First Quarter Financial Results
Date:5/7/2009

Inc. is a biotechnology company focused on developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, wh
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
(Date:6/2/2015)... GOJO, inventors of PURELL ® Advanced ... at the White House Forum.  GOJO was among 150 ... stakeholders at the White House Forum to announce commitments ... of antibiotic-resistant bacteria, detect resistant strains, preserve the efficacy ... resistant infections. "A primary prevention approach to ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... on health care, Jack Uldrich has been selected ... in New York today. He will deliver his ... , Uldrich has delivered presentations to the American ... of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
Breaking Biology Technology:Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... , Parallel Phase 2 studies could expedite development ... Oct. 16 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or ... the Company,s Annual General Meeting for shareholders highlighting ... drug, RVX-208, for the treatment of cardiovascular disease. ...
... Based on its annual assessment of companies making ... Agile Therapeutics, Inc. (Agile) with the 2009 North ... Year Award for its outstanding achievements in drug ... great potential as a convenient contraceptive option. Not ...
... , - New Neuroscience Research ... and Used by the National Institutes of,Health, Will be Showcased ... Elsevier, the leading publisher of scientific, technical and ... new,features it is rolling out for its BrainNavigator research tool ...
Cached Biology Technology:Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 2Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 3Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 4Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 2Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 3Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 4Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 5Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 2Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 3Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 4Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 5
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... powerful class of antioxidants could one day be a potent ... antioxidants called synthetic triterpenoids blocked development of Parkinson,s in an ... days, said Dr. Bobby Thomas, neuroscientist at the Medical College ... of the study in the journal Antioxidants & Redox ...
... Award for Innovative Excellence, the Society,s highest award. ... Fulwyler, the inventor of the electrostatic cell sorter, and ... Dr. Terstappen received his Ph.D. in Applied Physics from ... pioneering cytometry research at Becton Dickinson. In 1994, ...
... July 23, 2012 Scientists at Joslin Diabetes ... (GLP-1), a gut hormone, protects against kidney disease, and ... findings, which are reported today online by Diabetes, may ... harness the actions of GLP-1 to prevent the harmful ...
Cached Biology News:Powerful class of antioxidants may be potent Parkinson's treatment 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 3Joslin researchers gain new understanding of diabetes and kidney disease 2Joslin researchers gain new understanding of diabetes and kidney disease 3
... (IC50 = 59.2 M). Formula: ... O 13 MolWeight: ... RT CAS: ... to 100 mM in DMSO IUPAC: ...
POU domain, class 2, transcription factor 2,...
NAP-2 (5C7)...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
Biology Products: